Evidence map›Paper›PMID 39466792›Full record

ArticlePloS one2024

Rabex-5 E3 and Rab5 GEF domains differ in their regulation of Ras, Notch, and PI3K signaling in Drosophila wing development.

Theresa A Reimels, Mia Steinberg, Hua Yan, Sivan Shahar, Ashley Rosenberg, Kristina Kalafsky, Max Luf, Lindsay Kelly, Stacia Octaviani, Cathie M Pfleger

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Theresa A ReimelsDepartment of Oncological Sciences, Salt Lake City, Utah, United States of America.
Mia SteinbergDepartment of Oncological Sciences, Salt Lake City, Utah, United States of America.
Hua YanDepartment of Oncological Sciences, Salt Lake City, Utah, United States of America.
Sivan ShaharDepartment of Oncological Sciences, Salt Lake City, Utah, United States of America.
Ashley RosenbergDepartment of Oncological Sciences, Salt Lake City, Utah, United States of America.ORCID 0000-0001-9029-445X
Kristina KalafskyDepartment of Oncological Sciences, Salt Lake City, Utah, United States of America.
Max LufDepartment of Oncological Sciences, Salt Lake City, Utah, United States of America.ORCID 0009-0002-4055-8896
Lindsay KellyThe Graduate School of Biomedical Sciences, The Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.
Stacia OctavianiDepartment of Oncological Sciences, Salt Lake City, Utah, United States of America.
Cathie M PflegerDepartment of Oncological Sciences, Salt Lake City, Utah, United States of America.ORCID 0000-0001-8309-2235

Funding

Regulation of Ras in development by post-translational modificationR01GM135330 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PFLEGER, CATHIE M · 2020 to 2023
$1.4M
Rabex-5 regulation of Ras and Notch signaling in development and diseaseR01GM122995 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PFLEGER, CATHIE M · 2017 to 2020
$1.3M
NIGMS NIH HHS R01 GM122995NIGMS NIH HHS R01 GM135330
6 · The paper itself

Abstract

Rabex-5 (also called RabGEF1), a protein originally characterized for its Rab5 GEF function, also has an A20-like E3 ubiquitin ligase domain. We and others reported that Rabex-5 E3 activity promotes Ras mono- and di-ubiquitination to inhibit Ras signaling in Drosophila and mammals. Subsequently, we reported that Rabex-5 inhibits Notch signaling in the Drosophila hematopoietic system. Here we report genetic interactions using Rabex-5 transgenes encoding domain-specific mutations that show that Rabex-5 requires an intact E3 domain to inhibit Notch signaling in the epithelial tissue of the developing wing. Surprisingly, we discovered that Rabex-5 with an impaired E3 domain but active Rab5 GEF domain suppresses Notch loss-of-function phenotypes and enhances both Notch duplication phenotypes and activated Ras phenotypes consistent with a model that the Rab5 GEF activity of Rabex-5 might positively regulate Ras and Notch. Positive and negative regulation of developmental signaling by its different catalytic domains could allow Rabex-5 to precisely coordinate developmental signaling to fine-tune patterning. Finally, we report that Rabex-5 also inhibits the overgrowth due to loss of PTEN or activation of PI3K but not activation of AKT. Inhibition of Ras, Notch, and PI3K signaling may explain why Rabex-5 is deleted in some cancers. Paradoxically, Rabex-5 is reported to be an oncogene in other cancers. We propose that Rabex-5 acts as a tumor suppressor via its E3 activity to inhibit Ras, Notch, and PI3K signaling and as an oncogene via its Rab5 GEF activity to enhance Ras and Notch signaling.

Indexed as

Drosophila Proteinsrab5 GTP-Binding ProteinsSignal TransductionUbiquitin-Protein LigasesAnimalsDrosophilaDrosophila melanogasterGuanine Nucleotide Exchange FactorsPhosphatidylinositol 3-KinasesProtein Domainsras ProteinsReceptors, NotchWings, AnimalDrosophila ProteinsGuanine Nucleotide Exchange FactorsN protein, DrosophilaPhosphatidylinositol 3-Kinasesrab5 GTP-Binding ProteinsRab5 protein, DrosophilaRabex-5 protein, Drosophilaras ProteinsReceptors, NotchUbiquitin-Protein Ligases

Identifiers

PMID39466792
PMCPMC11515992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.